Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled ABPM trial of effects of vibegron on ambulatory blood pressure in patients with overactive bladder

X
Trial Profile

A randomized, double-blind, placebo-controlled ABPM trial of effects of vibegron on ambulatory blood pressure in patients with overactive bladder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vibegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms ABPM
  • Most Recent Events

    • 26 Apr 2024 According to Pierre Fabre media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSA. This CHMP positive opinion is supported by clinical data from the study URO-901-1001.
    • 22 May 2023 According to Pierre Fabre media release, the company has been started the EU marketing authorization application procedure for Vibegron in overactive bladder. This submission includes the data from this study.
    • 01 Apr 2022 Results characterizing the the blood pressure (BP) profile of the new beta3-adrenergic receptor agonist, vibegron, in patients with overactive bladder published in the Blood Pressure Monitoring

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top